SureTrader
Home > Boards > US Listed > Biotechs >

Ra Pharmaceuticals, Inc. (RARX)

RARX RSS Feed
Add RARX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 12/11/2017 7:29:26 PM - Followers: 0 - Board type: Free - Posts Today: 0

Ra Pharmaceuticals, Inc. 87 Cambridge Park Drive Cambridge Cambridge, MA 02140 United States 617-401-4060 http://www.rapharma.com Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP). The company's preclinical testing products include Factor D inhibition for age-related macular degeneration and geographic atrophy, as well as for Orphan renal dense deposit and C3 glomerulonephritis; Oral C5 inhibitor for PNH, rMG, LN, and central nervous system (CNS) diseases; and C1s inhibition for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
SureTrader
RARX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
RARX News: Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment 01/08/2018 07:12:00 AM
RARX News: Ra Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis Patients 12/21/2017 04:01:00 PM
RARX News: Current Report Filing (8-k) 12/08/2017 05:19:41 PM
RARX News: Ra Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference 12/07/2017 07:12:00 AM
RARX News: Ra Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria 12/04/2017 07:00:00 AM
PostSubject
#3   This seems to be a bit oversold. r clarke 12/11/17 07:29:26 PM
#2   Up and up? AD2000 05/15/17 09:32:14 PM
#1   RARX bullish 22.82 stocktrademan 04/16/17 04:04:12 PM
PostSubject